SMNR Semnur Pharmaceuticals, Inc.: institutional ownership and insider trading
2 funds reported holding $23 of Semnur Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net bought $73, with 2 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
SMNR revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.35M, EPS -0.02
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.58M, EPS -0.02
- Quarter ended Dec 31, 2025: revenue n/a, net income −$6.16M, EPS 0.00
- Quarter ended Sep 30, 2025: revenue n/a, net income −$153M, EPS -0.76
Largest institutional holders of SMNR
- RHUMBLINE ADVISERS — $15
- GAMMA Investing LLC — $8
Recent SMNR insider trades
- Sep 23, 2025: Scilex Holding Co sold 12,500,000 shares ($200M)
5%+ owners
- Scilex Holding Company: 78.9% (Schedule 13D/A, filed Jun 26, 2026)
Who owns the most SMNR stock?
The largest institutional holders of Semnur Pharmaceuticals, Inc. in the latest 13F filings are RHUMBLINE ADVISERS ($15), GAMMA Investing LLC ($8).
Are insiders buying or selling SMNR?
No open-market insider buys or sells of Semnur Pharmaceuticals, Inc. were reported in the last 12 months.